HBM Holdings Limited Announces Commenced Collaborations on Antibody-Drug Conjugate Projects with Legochem Biosciences Inc. and Duality Biotherapeutics
tumor to Duality Biologics to develop the world's first-in-class ADCs based on Duality Biologics' Duality Immune Toxin Antibody Conjugate platform. The Company also entered into a license agreement with LegoChem Biosciences in 2022, over an antibody for ADC. The agreement also contemplated that the contracting parties may collaborate in developing the ADC for therapeutic applications.